IRAK3
MOLECULAR TARGETinterleukin 1 receptor associated kinase 3
IRAK3 (interleukin 1 receptor associated kinase 3) is targeted by 36 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting IRAK3
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | gefitinib | 5.67 | 290 |
| 2 | foretinib | 4.34 | 76 |
| 3 | tozasertib | 4.33 | 75 |
| 4 | midostaurin | 3.85 | 46 |
| 5 | pazopanib | 3.69 | 39 |
| 6 | nintedanib | 3.61 | 36 |
| 7 | canertinib | 3.53 | 33 |
| 8 | bms 387032 | 3.47 | 31 |
| 9 | tae 684 | 3.43 | 30 |
| 10 | fedratinib | 3.40 | 29 |
| 11 | gilteritinib | 3.40 | 29 |
| 12 | mln 8054 | 3.33 | 27 |
| 13 | sgi 1776 | 3.26 | 25 |
| 14 | tandutinib | 3.22 | 24 |
| 15 | omipalisib | 3.14 | 22 |
| 16 | jnj 7706621 | 3.09 | 21 |
| 17 | lestaurtinib | 3.04 | 20 |
| 18 | pacritinib | 3.04 | 20 |
| 19 | defosbarasertib | 2.89 | 17 |
| 20 | r 406 | 2.83 | 16 |
| 21 | k 252a | 2.83 | 16 |
| 22 | milciclib | 2.77 | 15 |
| 23 | pha 665752 | 2.71 | 14 |
| 24 | crenolanib | 2.71 | 14 |
| 25 | azd 5438 | 2.71 | 14 |
| 26 | kw 2449 | 2.64 | 13 |
| 27 | zotiraciclib | 2.56 | 12 |
| 28 | mk 5108 | 2.48 | 11 |
| 29 | gsk 461364 | 2.40 | 10 |
| 30 | su 014813 | 2.20 | 8 |
| 31 | cyc 116 | 2.08 | 7 |
| 32 | mk 2461 | 2.08 | 7 |
| 33 | fostamatinib | 2.08 | 7 |
| 34 | gsk 1059615 | 1.95 | 6 |
| 35 | Crizotinib | 1.10 | 2 |
| 36 | pictilisib | 0.69 | 1 |
About IRAK3 as a Drug Target
IRAK3 (interleukin 1 receptor associated kinase 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 36 compounds with documented IRAK3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
IRAK3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.